Product Code: RP-ID-10070786 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10070786
Market Overview:
Breast Cancer Therapy Market Segmentation by Therapy (Hormonal Therapy, Targeted Therapy, Immunotherapy, and Chemotherapy); by Cancer Type [In situ {Ductal Carcinoma In Situ (DCIS)}, and Invasive {Invasive Ductal Carcinoma (IDC), and Invasive Lobular Carcinoma (ILC)}]; and by Route of Administration (Oral, and Injectable)-Global Demand Analysis & Opportunity Outlook 2031
Global Breast Cancer Therapy Market Highlights Over 2022 - 2031
The global breast cancer therapy market generated a revenue figure of approximately USD 26 billion in the year 2021 and is projected to grow at a CAGR of ~10% over the forecast period, i.e., 2022 – 2031. The growth of the market can primarily be attributed to the growing incidences of breast cancer, and budding investment in research and development of technology for cancer treatment. According to the World Health Organization (WHO), in the year 2020, 2.3 million women were diagnosed with breast cancer worldwide. According to the American Cancer Society Inc., in the United States, average risk for a woman to develop breast cancer at any point of life is about 13%. Moreover, the development & launch of new screening programs, and introduction of new pharmaceutical drugs for the cancerous treatment is expected to drive the market growth. Further, the initiatives taken by government to spread awareness about the treatment options and organizing free camps and workshops is projected to boost the market growth.
CLICK TO DOWNLOAD A SAMPLE REPORT
Breast cancer is cancer that develops in the breast and spreads to other parts of the body. It can begin in either one or both of the breasts. The breast is an organ located over the upper ribs and chest muscles. A lump in the breast, blood flow from the nipple, and changes in the form or texture of the nipple or breast are all signs of breast cancer.
The global breast cancer therapy market is segmented on the basis of therapy, cancer type, and route of administration. Among these, the therapy segment is divided into targeted therapy, hormonal therapy, chemotherapy, and immunotherapy. The targeted therapy segment is anticipated to hold the largest market size in value and is estimated to grow at a notable CAGR over the forecast period. Targeted therapies are drugs or elements that stop the spread of cancer by creating interference with specific molecules that helps in the growth and progression of cancer. The growth of the segment can be associated with the versatile nature of targeted therapy to pool with other therapies in order to show effective results against cancer disease. Moreover, the research and development in clinical studies for targeted therapy is anticipated to create major opportunities for the growth of the segment in the coming years.
Global Breast Cancer Therapy Market Regional Synopsis
Regionally, the global breast cancer therapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in North America held the largest market share in the year 2021 as a result of the growing prevalence of breast cancer and developed healthcare infrastructure. In the other statistics by the American Cancer Society, Inc., in the United States, nearly 1 in 3 females are diagnosed with breast cancer each year. Besides, increased investment by pharmaceuticals company in research and development along with the rapid adoption of new technologies among healthcare professionals are major factors driving the market growth in this region. Alternatively, the market in the Asia Pacific region is projected to witness rapid growth by growing at a higher CAGR over the forecast period. The growth of the market can be attributed to the constant development in healthcare infrastructure, along with the government’s support services and initiatives to create awareness regarding cancer treatment among the public. Further, the rising cases of breast cancer in the region are expected to boost the market growth majorly in this region. According to the Organization for Economic Co-operation and Development (OECD), nearly 839000 women were diagnosed with breast cancer in the year 2018 in the Asia Pacific region.
Market Segmentation
Our in-depth analysis of the global breast cancer therapy market includes the following segments:
By Therapy
-
Hormonal Therapy
-
Targeted Therapy
-
Immunotherapy
-
Chemotherapy
By Cancer Type
- In situ
-
Ductal Carcinoma In situ (DCIS)
- Invasive
-
Invasive Ductal Carcinoma (IDC)
-
Invasive Lobular Carcinoma (ILC)
By Route of Administration
-
Oral
-
Injectable
Growth Drivers and Challenges Impacting the Growth of the Global Breast Cancer Therapy Market
Growth Drivers
-
Growing cases of breast cancer
-
Increasing investment in research and development
-
Rapid launch of new screening programs
-
Growing development of pharmaceutical drugs
-
Support initiatives by the government in spreading awareness
Challenges
-
High cost of treatment
-
Concern for aftereffects of therapy
Key Companies Dominating the Global Breast Cancer Therapy Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global breast cancer therapy market that are included in our report are Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., PerkinElmer Inc., and Zimmer Biomet among others.
Latest Developments in the Global Breast Cancer Therapy Market:
-
11 March 2022: AstraZeneca and Merck announced that the U.S Food and Drug Administration (FDA), has approved LYNPARZA for adjuvant treatment for patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have received neoadjuvant or adjuvant chemotherapy in the past.
-
13 June 2019: The U.S. Food and Drug Administration (FDA) approved KANJINTI, developed by Amgen and Allergan plc to treat patients with HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Amgen Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline plc
- Merck & Co.Inc.
- Novartis AG
- Pfizer Inc.
- PerkinElmer Inc.
- Zimmer Biomet
Related Reports
Proof of Quality & Reliability
